Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ENROLLING_BY_INVITATION

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced/Metastatic Cancer

Interventions

DRUG: futibatinib
DRUG: futibatinib, fulvestrant

Sponsor

Taiho Oncology, Inc.